EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer

Ana Gil-Torralvo, M Ángeles Domínguez-Cejudo, Sonia Molina-Pinelo, Carmen Garrigós, Marta Benavent-Viñuales, Alejandro Falcón, Mónica Cejuela, Beatriz Rodríguez-Alonso, Javier Pascual, Manuel Ruíz-Borrego, Javier Salvador-Bofill

Breast Cancer · 2026-05 · 33 (3) · 634-643

DOI: 10.1007/s12282-026-01840-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, online erschienen am 06.03.2026. Verfasst von Ana Gil-Torralvo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Virgen del Rocio Hospital, Avenida Manuel Siurot sn, Seville, 41013, Spain. anagil886@gmail.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, Glucuronosyltransferase, Minor Histocompatibility Antigens. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche, Consejería de Salud y Familias, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pathological complete response (pCR) after neoadjuvant therapy is a robust surrogate marker for long-term outcomes in breast cancer. Despite major advances with targeted therapies, a significant proportion of patients fail to achieve pCR, underscoring the urgent need for reliable biomarkers that can predict treatment response and guide patient stratification.

Methods

We conducted a two-phase study including 53 patients with HER2-positive, hormone receptor–negative breast cancer treated with neoadjuvant chemotherapy plus anti-HER2 agents. Transcriptomic profiling (discovery cohort, n = 13) identified differentially expressed genes associated with therapeutic response, which were validated by qPCR in an independent cohort ( n = 40). Functional enrichment analysis was performed to explore the biological pathways underlying the differential response.

Results

Differential expression analysis revealed 6251 genes associated with response, with significant enrichment in xenobiotic metabolism and steroid hormone biosynthesis pathways. Within these, members of the UGT2B family (UGT2B10, UGT2B17, UGT2B28) were overexpressed in non-responders. Validation confirmed UGT2B17 ( p = 0.023, AUC = 0.699, sensitivity 77.2%, specificity 64.5%) and UGT2B28 ( p = 0.046, AUC = 0.677) as predictive biomarkers of resistance to neoadjuvant therapy. UGT2B17 showing the highest discriminative value.

Conclusions

UGT2B17 overexpression is associated with resistance to neoadjuvant therapy in HER2-positive breast cancer, supporting its potential role as a predictive biomarker. Integration of UGT2B17 into molecular panels could improve patient stratification and guide personalized therapeutic strategies in this subtype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBiomarkers, TumorGlucuronosyltransferaseMinor Histocompatibility AntigensAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleErb-b2 Receptor Tyrosine KinasesPathologic Complete ResponseNeoadjuvant TherapyMiddle AgedGene Expression ProfilingAdultAgedPrognosisDrug Resistance, Neoplasm

Stichwörter der Autor:innen

HER2-positive breast cancerNeoadjuvant therapyPathological complete responsePredictive biomarkerUGT2B17

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorGlucuronosyltransferaseERBB2 protein, humanUGT2B17 protein, humanMinor Histocompatibility Antigens

Autor:innen und Institutionen

  • Medical Oncology Department, Virgen del Rocio Hospital, Avenida Manuel Siurot sn, Seville, 41013, Spain. anagil886@gmail.com.
  • Institute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, Seville, Spain. anagil886@gmail.com.
  • Institute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, Seville, Spain.
  • Medical Oncology Department, Virgen del Rocio Hospital, Avenida Manuel Siurot sn, Seville, 41013, Spain.
  • Spanish Center for Biomedical Research Network in Oncology (CIBERONC), Madrid, Spain.
  • Department of Pharmacology, Faculty of Pharmacy, Universidad de Sevilla, Seville, Spain.

Förderung

  • F. Hoffmann-La Roche
  • Consejería de Salud y Familias, Junta de Andalucía

Zitieren

APA

Gil-Torralvo, A., Domínguez-Cejudo, M. Á., Molina-Pinelo, S., Garrigós, C., Benavent-Viñuales, M., Falcón, A., Cejuela, M., Rodríguez-Alonso, B., Pascual, J., Ruíz-Borrego, M., & Salvador-Bofill, J. (2026). UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer. Breast Cancer, 33(3), 634-643. https://doi.org/10.1007/s12282-026-01840-9

Vancouver

Gil-Torralvo A, Domínguez-Cejudo MÁ, Molina-Pinelo S, Garrigós C, Benavent-Viñuales M, Falcón A, et al. UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer. Breast Cancer. 2026;33(3):634-643. doi:10.1007/s12282-026-01840-9

BibTeX
@article{GilTorralvo2026,
  author = {Gil-Torralvo, Ana and Domínguez-Cejudo, M Ángeles and Molina-Pinelo, Sonia and Garrigós, Carmen and Benavent-Viñuales, Marta and Falcón, Alejandro and Cejuela, Mónica and Rodríguez-Alonso, Beatriz and Pascual, Javier and Ruíz-Borrego, Manuel and Salvador-Bofill, Javier},
  title = {UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer},
  journal = {Breast Cancer},
  year = {2026},
  volume = {33},
  number = {3},
  pages = {634--643},
  doi = {10.1007/s12282-026-01840-9}
}
Kostenlos starten →